Genentech in-licenses prostate cancer program

Genentech has agreed to license an experimental therapy for prostate cancer from Protein Design Labs. No details were released, but Protein Design will receive an upfront fee and milestones for the successful development of a therapy. Protein Design had originally in-licensed the program from Seattle Genetics.

- read this story from the AP for more